PL424453A1 - Sposoby zmniejszania szkodliwego działania niedoboru perfuzji narządów miąższowych przez inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) - Google Patents

Sposoby zmniejszania szkodliwego działania niedoboru perfuzji narządów miąższowych przez inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP)

Info

Publication number
PL424453A1
PL424453A1 PL424453A PL42445318A PL424453A1 PL 424453 A1 PL424453 A1 PL 424453A1 PL 424453 A PL424453 A PL 424453A PL 42445318 A PL42445318 A PL 42445318A PL 424453 A1 PL424453 A1 PL 424453A1
Authority
PL
Poland
Prior art keywords
endopeptidase
hsep
nep
reduce
human soluble
Prior art date
Application number
PL424453A
Other languages
English (en)
Inventor
Christopher Turski
Original Assignee
Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością filed Critical Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością
Priority to PL424453A priority Critical patent/PL424453A1/pl
Priority to EP19747045.3A priority patent/EP3746107A4/en
Priority to CA3088969A priority patent/CA3088969A1/en
Priority to MX2020007990A priority patent/MX2020007990A/es
Priority to KR1020207025024A priority patent/KR20200116144A/ko
Priority to PCT/PL2019/000013 priority patent/WO2019151883A1/en
Priority to CN201980011178.7A priority patent/CN111989112A/zh
Priority to RU2020125051A priority patent/RU2782919C2/ru
Priority to US16/964,984 priority patent/US12337001B2/en
Publication of PL424453A1 publication Critical patent/PL424453A1/pl
Priority to ZA2019/05958A priority patent/ZA201905958B/en
Priority to IL275994A priority patent/IL275994B1/en
Priority to US19/244,974 priority patent/US20250312354A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
    • C07F3/04—Calcium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/5532—Seven-(or more) membered rings
    • C07F9/5535—Seven-(or more) membered rings condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

Zgłoszenie dotyczy nowego zastosowania pochodnych benzazepiny, benzoksazepiny, kwasu benzotiazepino-N-octowego oraz fosfono-podstawionego benzazepinonu o aktywności hamującej obojętną endopeptydazę (NEP) i/lub ludzką rozpuszczalną endopeptydazę (hSEP). Związki te są stosowane do wytwarzania kompozycji farmaceutycznych zmniejszających szkodliwy wpływ bezobjawowo postępującego rozsianego niedoboru perfuzji narządów miąższowych, lub ich części, mogącego sugerować rozwój chorób układowych.
PL424453A 2018-01-31 2018-01-31 Sposoby zmniejszania szkodliwego działania niedoboru perfuzji narządów miąższowych przez inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) PL424453A1 (pl)

Priority Applications (12)

Application Number Priority Date Filing Date Title
PL424453A PL424453A1 (pl) 2018-01-31 2018-01-31 Sposoby zmniejszania szkodliwego działania niedoboru perfuzji narządów miąższowych przez inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP)
PCT/PL2019/000013 WO2019151883A1 (en) 2018-01-31 2019-01-31 Neutral endopeptidase (nep) and human soluble endopeptidase (hsep) inhibitors to reduce harmful effects of perfusion deficiency of organs
CA3088969A CA3088969A1 (en) 2018-01-31 2019-01-31 Neutral endopeptidase (nep) and human soluble endopeptidase (hsep) inhibitors to reduce harmful effects of perfusion deficiency of organs
MX2020007990A MX2020007990A (es) 2018-01-31 2019-01-31 Inhibidores de endopeptidasa neutra (nep) y endopeptidasa soluble humana (hsep) para reducir efectos perjudiciales de la deficiencia de perfusion de organos.
KR1020207025024A KR20200116144A (ko) 2018-01-31 2019-01-31 기관의 관류 결핍의 해로운 효과를 감소시키기 위한 중성 엔도펩티다제 (NEP) 및 사람 용해성 엔도펩티다제 (hSEP) 억제제
EP19747045.3A EP3746107A4 (en) 2018-01-31 2019-01-31 NEUTRAL ENDOPEPTIDASE (NEP) AND HUMAN SOLUBLE ENDOPEPTIDASE (HSEP) INHIBITORS TO REDUCE THE HARMFUL EFFECTS OF IMPROPER CIRCULATION OF ORGANS
CN201980011178.7A CN111989112A (zh) 2018-01-31 2019-01-31 用于减少器官灌流不足的有害效应的中性内肽酶(nep)及人类可溶性内肽酶(hsep)抑制剂
RU2020125051A RU2782919C2 (ru) 2018-01-31 2019-01-31 ИНГИБИТОРЫ НЕЙТРАЛЬНОЙ ЭНДОПЕПТИДАЗЫ (НЭП) И РАСТВОРИМОЙ ЭНДОПЕПТИДАЗЫ ЧЕЛОВЕКА (РЭПч) ДЛЯ УМЕНЬШЕНИЯ ВРЕДНЫХ ВОЗДЕЙСТВИЙ ПЕРФУЗИОННОГО ДЕФИЦИТА ОРГАНОВ
US16/964,984 US12337001B2 (en) 2018-01-31 2019-01-31 Neutral endopeptidase (NEP) and human soluble endopeptidase (hSEP) inhibitors to reduce detrimental effects of perfusion deficiency of parenchymal organs
ZA2019/05958A ZA201905958B (en) 2018-01-31 2019-09-10 Neutral endopeptidase (nep) and human soluble endopeptidase (hsep) inhibitors to reduce harmful effects of perfusion deficiency of organs
IL275994A IL275994B1 (en) 2018-01-31 2020-07-12 Benzazepine n-acetic acid derivatives and benzazepinone-n-acetic acid derivatives containing a phosphonic acid group, for use in reducing organ hypoperfusion
US19/244,974 US20250312354A1 (en) 2018-01-31 2025-06-20 Neutral endopeptidase (nep) and human soluble endopeptidase (hsep) inhibitors to reduce detrimental effects of perfusion deficiency of parenchymal organs

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL424453A PL424453A1 (pl) 2018-01-31 2018-01-31 Sposoby zmniejszania szkodliwego działania niedoboru perfuzji narządów miąższowych przez inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP)

Publications (1)

Publication Number Publication Date
PL424453A1 true PL424453A1 (pl) 2019-08-12

Family

ID=67478773

Family Applications (1)

Application Number Title Priority Date Filing Date
PL424453A PL424453A1 (pl) 2018-01-31 2018-01-31 Sposoby zmniejszania szkodliwego działania niedoboru perfuzji narządów miąższowych przez inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP)

Country Status (10)

Country Link
US (2) US12337001B2 (pl)
EP (1) EP3746107A4 (pl)
KR (1) KR20200116144A (pl)
CN (1) CN111989112A (pl)
CA (1) CA3088969A1 (pl)
IL (1) IL275994B1 (pl)
MX (1) MX2020007990A (pl)
PL (1) PL424453A1 (pl)
WO (1) WO2019151883A1 (pl)
ZA (1) ZA201905958B (pl)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL184336B1 (pl) * 1995-03-23 2002-10-31 Solvay Pharm Gmbh Pochodne kwasu benzazepino-, benzoksazepino-i benzotiazepino-N-octowego, sposób ich wytwarzania oraz zawierające je środki lecznicze
EP1706121A1 (en) * 2004-01-12 2006-10-04 Solvay Pharmaceuticals B.V. Neutral endopeptidase (nep) and human soluble endopeptidase (hsep) inhibitors for prophylaxis and treatment of neurodegenerative disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19638020A1 (de) * 1996-09-18 1998-03-19 Solvay Pharm Gmbh Die gastrointestinale Durchblutung fördernde Arzneimittel
DE19750002A1 (de) 1997-11-12 1999-05-20 Solvay Pharm Gmbh Phosphonsäure-substituierte Benzazepinon-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
EP1468010A1 (en) 2002-01-16 2004-10-20 Solvay Pharmaceuticals B.V. Solid salts benzazepine compounds and their use in the preparation of pharmaceuticals compounds
AR038681A1 (es) 2002-02-14 2005-01-26 Solvay Pharm Bv Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua
WO2004062692A1 (en) 2003-01-13 2004-07-29 Solvay Pharmaceuticals B.V. Formulation of poorly water-soluble active substances
EP1687006B1 (en) * 2003-11-18 2007-11-14 Solvay Pharmaceuticals GmbH Pharmaceutical compositions for the treatment of renal dysfunction
US7232813B2 (en) * 2004-01-12 2007-06-19 Solvay Pharmaceuticals B.V. Neutral endopeptidase (NEP) and human soluble endopeptidase (hSEP) inhibitors for prophylaxis and treatment of neuro-degenerative disorders
WO2005112939A1 (en) * 2004-05-14 2005-12-01 Solvay Pharmaceuticals Gmbh Medicaments containing dually acting inhibitors of neutral endopeptidase and of human soluble endopeptidase for the treatment of sexual dysfunction
PL424452A1 (pl) 2018-01-31 2019-08-12 Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu
US20230118503A1 (en) 2020-07-19 2023-04-20 Christopher Turski NEUTRAL ENDOPEPTIDASE (NEP) AND HUMAN SOLUBLE ENDOPEPTIDASE (hSEP) INHIBITORS FOR PROPHYLAXIS AND TREATMENT OF EYE DISEASES

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL184336B1 (pl) * 1995-03-23 2002-10-31 Solvay Pharm Gmbh Pochodne kwasu benzazepino-, benzoksazepino-i benzotiazepino-N-octowego, sposób ich wytwarzania oraz zawierające je środki lecznicze
EP1706121A1 (en) * 2004-01-12 2006-10-04 Solvay Pharmaceuticals B.V. Neutral endopeptidase (nep) and human soluble endopeptidase (hsep) inhibitors for prophylaxis and treatment of neurodegenerative disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BOGNA BROCKHUIS, ZABURZENIA PERFUZJI MÓZGOWEJ OCENIONE METODĄ TOMOGRAFII EMISYJNEJ POJEDYNCZEGO FOTONU (SPECT) U PACJENTÓW Z OTĘPIENIEM Z CIAŁAMI LEWY'EGO, CHOROBĄ PARKINSONA ORAZ CHOROBĄ ALZHEIMERA, 2009 *

Also Published As

Publication number Publication date
EP3746107A1 (en) 2020-12-09
RU2020125051A3 (pl) 2022-02-28
RU2020125051A (ru) 2022-02-28
US12337001B2 (en) 2025-06-24
ZA201905958B (en) 2021-07-28
WO2019151883A1 (en) 2019-08-08
EP3746107A4 (en) 2022-01-12
IL275994B1 (en) 2026-03-01
CA3088969A1 (en) 2019-08-08
US20250312354A1 (en) 2025-10-09
IL275994A (en) 2020-08-31
US20210047352A1 (en) 2021-02-18
CN111989112A (zh) 2020-11-24
KR20200116144A (ko) 2020-10-08
MX2020007990A (es) 2020-09-09

Similar Documents

Publication Publication Date Title
DOP2025000288A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
CO2022003782A2 (es) Inhibidores de kras g12d
CO2020000145A2 (es) Carboxamidas como moduladores de los canales de sodio
MX2015009591A (es) Amidas como moduladores de canales de sodio.
MX2015009602A (es) Piridona amidas como moduladores de canales de sodio.
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
PY1923494A (es) Derivados de n-(3-(7h-pirrolo[2,3-d]pirimidin-4-il)fenil)benzamida
EA201690848A1 (ru) Производные бициклического пиридила с конденсированными кольцами в качестве ингибиторов fgfr4
MX388533B (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
CL2013000304A1 (es) Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
MA47356B1 (fr) Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases
PH12016500024A1 (en) Bromodomain inhibitor
EA201590118A1 (ru) Производные пирролидина и их применение в качестве модуляторов пути активации комплемента
SV2010003559A (es) Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos
DOP2013000104A (es) Antagonistas de mdm2 de espiro-oxindol
GT200900192A (es) Derivados de imidazol como inhibidores de proteina de uso de cinesina (eg-5).-
MX2022001789A (es) Derivados de 2-hidroxicicloalcan-1-carbamoilo.
UY35293A (es) Isotiazoles sustituidos con amino
UY35275A (es) Derivados de aminopirazina
EA202191114A1 (ru) Производные пиридинилсульфонамида, фармацевтические композиции и их применение
EA201591541A1 (ru) Ингибиторы бета-секретазы 1 (bace 1)
PE20130191A1 (es) Combinaciones que contienen 2, 3-dihidroimidazo[1, 2-c]quinazolina sustituida
JOP20190053A1 (ar) مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط